Sphera Funds Management LTD Has Increased By $1.95 Million Its Immunomedics (IMMU) Holding, Shorts at Collegium Pharmaceutical (COLL) Lowered By 1.48%

June 19, 2017 - By Clifton Ray

Collegium Pharmaceutical Incorporated (NASDAQ:COLL) had a decrease of 1.48% in short interest. COLL’s SI was 5.10M shares in June as released by FINRA. Its down 1.48% from 5.18 million shares previously. With 466,500 avg volume, 11 days are for Collegium Pharmaceutical Incorporated (NASDAQ:COLL)’s short sellers to cover COLL’s short positions. The SI to Collegium Pharmaceutical Incorporated’s float is 26.8%. About 181,712 shares traded. Collegium Pharmaceutical Inc (NASDAQ:COLL) has declined 44.24% since June 19, 2016 and is downtrending. It has underperformed by 60.94% the S&P500.

Sphera Funds Management Ltd increased Immunomedics Inc (IMMU) stake by 162.5% reported in 2016Q4 SEC filing. Sphera Funds Management Ltd acquired 650,000 shares as Immunomedics Inc (IMMU)’s stock rose 37.64%. The Sphera Funds Management Ltd holds 1.05M shares with $3.85M value, up from 400,000 last quarter. Immunomedics Inc now has $839.74M valuation. The stock rose 4.95% or $0.37 reaching $7.85 per share. About 1.09M shares traded. Immunomedics, Inc. (NASDAQ:IMMU) has risen 76.26% since June 19, 2016 and is uptrending. It has outperformed by 59.56% the S&P500.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The company has market cap of $328.50 million. The Firm is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. It currently has negative earnings. The Company’s products include Xtampza ER and ONSOLIS.

Among 2 analysts covering Collegium Pharmaceutical Inc (NASDAQ:COLL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Collegium Pharmaceutical Inc had 2 analyst reports since February 19, 2016 according to SRatingsIntel. Gabelli initiated the shares of COLL in report on Tuesday, September 13 with “Buy” rating. William Blair initiated it with “Outperform” rating and $35 target in Friday, February 19 report.

Investors sentiment increased to 2.07 in 2016 Q4. Its up 1.24, from 0.83 in 2016Q3. It is positive, as 13 investors sold IMMU shares while 16 reduced holdings. 18 funds opened positions while 42 raised stakes. 59.48 million shares or 20.52% more from 49.35 million shares in 2016Q3 were reported. Susquehanna Intl Grp Llp stated it has 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Proshare Limited has invested 0% in Immunomedics, Inc. (NASDAQ:IMMU). Goldman Sachs Gru Inc accumulated 0% or 150,126 shares. Blackrock reported 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Parametric Assoc Limited Liability Company invested in 0% or 111,685 shares. Morgan Stanley has invested 0% in Immunomedics, Inc. (NASDAQ:IMMU). Voya Invest Ltd Liability holds 0% or 47,625 shares. Blackrock Mgmt Ltd Liability Corporation owns 360,037 shares for 0% of their portfolio. Raymond James Financial Advisors has 0% invested in Immunomedics, Inc. (NASDAQ:IMMU). Paloma Prns Management Com stated it has 100,000 shares or 0% of all its holdings. Barclays Public Limited Liability Co invested in 0% or 129,077 shares. Point72 Asset Mgmt Ltd Partnership reported 68,400 shares. Fmr Limited Com holds 0% or 1.13 million shares in its portfolio. 4.70 million were accumulated by Acuta Prtnrs Ltd Company. Pura Vida Ltd Liability Corp accumulated 336,500 shares.

Sphera Funds Management Ltd decreased Colucid Pharmaceuticals Inc stake by 42,000 shares to 358,000 valued at $13.03M in 2016Q4. It also reduced Immune Design Corp (NASDAQ:IMDZ) stake by 100,000 shares and now owns 103,000 shares. Snap On Inc (NYSE:SNA) was reduced too.

Among 3 analysts covering Immunomedics (NASDAQ:IMMU), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Immunomedics had 7 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was downgraded by Wells Fargo on Friday, December 4 to “Market Perform”. Jefferies upgraded it to “Buy” rating and $5 target in Friday, May 6 report. Jefferies maintained the shares of IMMU in report on Tuesday, March 15 with “Hold” rating. As per Thursday, October 6, the company rating was reinitiated by Jefferies. Wells Fargo downgraded the stock to “Market Perform” rating in Tuesday, June 21 report. The stock has “Hold” rating by Jefferies on Wednesday, July 29.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: